Go Pro
NASDAQ:BNR

Burning Rock Biotech Q1 2026 Earnings Report

Burning Rock Biotech logo
$18.60 +0.60 (+3.33%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$18.84 +0.24 (+1.32%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Burning Rock Biotech EPS Results

Actual EPS
-$0.20
Consensus EPS
-$2.29
Beat/Miss
Beat by +$2.09
One Year Ago EPS
N/A

Burning Rock Biotech Revenue Results

Actual Revenue
$15.66 million
Expected Revenue
$19.21 million
Beat/Miss
Missed by -$3.55 million
YoY Revenue Growth
N/A

Burning Rock Biotech Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Tuesday, June 9, 2026
Conference Call Time
6:00AM ET

Upcoming Earnings

Burning Rock Biotech's Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 20, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Burning Rock Biotech Earnings Headlines

Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
Burning Rock Reports Second Quarter 2026 Financial Results
See More Burning Rock Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Burning Rock Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Burning Rock Biotech and other key companies, straight to your email.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ:BNR) Limited is a biotechnology company focused on precision oncology. The company develops and commercializes next-generation sequencing (NGS)-based tests designed to support cancer screening, diagnosis, treatment selection and disease monitoring.

Its products and services include tumor profiling and liquid biopsy tests that analyze genetic changes associated with cancer. Burning Rock also provides testing services to hospitals, physicians and biopharmaceutical companies, including services intended to help identify patients for clinical trials and evaluate targeted cancer therapies.

Founded in 2014, Burning Rock is headquartered in Guangzhou, China, and primarily serves the Chinese healthcare and pharmaceutical markets, with additional activities connected to international clinical development. The company was listed on the Nasdaq Global Select Market in 2020. Burning Rock was founded and is led by Yusheng Huang, who serves as chief executive officer.

View Burning Rock Biotech Profile